Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

Pablo J. Cagnoni, Thomas J. Walsh, Mary M. Prendergast, David Bodensteiner, Sharon Hiemenz, Richard N. Greenberg, Carola A.S. Arndt, Mindy Schuster, Nita Seibel, Vijay Yeldandi, Kuo B. Tong

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: In a randomized, double-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients, using a composite end point, but was more effective in reducing proven emergent fungal infections, infusion-related toxicities, and nephrotoxicity. The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional therapy. Patients and Methods: Itemized hospital billing data were collected on 414 patients from 19 of the 32 centers that participated in the trial. Hospital length of stay and costs from the first dose of study medication to the time of hospital discharge were assessed. Results: Hospital costs from the time of first dose to discharge were significantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P = .022). However, hospital costs were highly sensitive to the cost of study medication ($39,648 v $43,048 when drug costs were not included; P = .416). Using decision analysis models and sensitivity analyses to vary the cost of study medications and the risk of nephrotoxicity, the break-even points for the cost of liposomal therapy were calculated to range from $72 to $87 per 50 mg for all patients and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients. Conclusion: The cost of liposomal amphotericin B and patient risk for developing nephrotoxicity play large roles in determining whether liposomal amphotericin B is cost-effective as first-line empirical therapy in persistently febrile neutropenic patients. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)2476-2483
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number12
StatePublished - Jun 2000

Fingerprint

Pharmaceutical Economics
Amphotericin B
Fever
Hospital Costs
Costs and Cost Analysis
Therapeutics
Length of Stay
Drug Costs
Decision Support Techniques
liposomal amphotericin B
Mycoses
Multicenter Studies
Bone Marrow
Transplants

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cagnoni, P. J., Walsh, T. J., Prendergast, M. M., Bodensteiner, D., Hiemenz, S., Greenberg, R. N., ... Tong, K. B. (2000). Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Clinical Oncology, 18(12), 2476-2483.

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. / Cagnoni, Pablo J.; Walsh, Thomas J.; Prendergast, Mary M.; Bodensteiner, David; Hiemenz, Sharon; Greenberg, Richard N.; Arndt, Carola A.S.; Schuster, Mindy; Seibel, Nita; Yeldandi, Vijay; Tong, Kuo B.

In: Journal of Clinical Oncology, Vol. 18, No. 12, 06.2000, p. 2476-2483.

Research output: Contribution to journalArticle

Cagnoni, PJ, Walsh, TJ, Prendergast, MM, Bodensteiner, D, Hiemenz, S, Greenberg, RN, Arndt, CAS, Schuster, M, Seibel, N, Yeldandi, V & Tong, KB 2000, 'Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients', Journal of Clinical Oncology, vol. 18, no. 12, pp. 2476-2483.
Cagnoni, Pablo J. ; Walsh, Thomas J. ; Prendergast, Mary M. ; Bodensteiner, David ; Hiemenz, Sharon ; Greenberg, Richard N. ; Arndt, Carola A.S. ; Schuster, Mindy ; Seibel, Nita ; Yeldandi, Vijay ; Tong, Kuo B. / Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 12. pp. 2476-2483.
@article{bf76ba2912d34aee8025ce88b59006eb,
title = "Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients",
abstract = "Purpose: In a randomized, double-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients, using a composite end point, but was more effective in reducing proven emergent fungal infections, infusion-related toxicities, and nephrotoxicity. The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional therapy. Patients and Methods: Itemized hospital billing data were collected on 414 patients from 19 of the 32 centers that participated in the trial. Hospital length of stay and costs from the first dose of study medication to the time of hospital discharge were assessed. Results: Hospital costs from the time of first dose to discharge were significantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P = .022). However, hospital costs were highly sensitive to the cost of study medication ($39,648 v $43,048 when drug costs were not included; P = .416). Using decision analysis models and sensitivity analyses to vary the cost of study medications and the risk of nephrotoxicity, the break-even points for the cost of liposomal therapy were calculated to range from $72 to $87 per 50 mg for all patients and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients. Conclusion: The cost of liposomal amphotericin B and patient risk for developing nephrotoxicity play large roles in determining whether liposomal amphotericin B is cost-effective as first-line empirical therapy in persistently febrile neutropenic patients. (C) 2000 by American Society of Clinical Oncology.",
author = "Cagnoni, {Pablo J.} and Walsh, {Thomas J.} and Prendergast, {Mary M.} and David Bodensteiner and Sharon Hiemenz and Greenberg, {Richard N.} and Arndt, {Carola A.S.} and Mindy Schuster and Nita Seibel and Vijay Yeldandi and Tong, {Kuo B.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "18",
pages = "2476--2483",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

AU - Cagnoni, Pablo J.

AU - Walsh, Thomas J.

AU - Prendergast, Mary M.

AU - Bodensteiner, David

AU - Hiemenz, Sharon

AU - Greenberg, Richard N.

AU - Arndt, Carola A.S.

AU - Schuster, Mindy

AU - Seibel, Nita

AU - Yeldandi, Vijay

AU - Tong, Kuo B.

PY - 2000/6

Y1 - 2000/6

N2 - Purpose: In a randomized, double-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients, using a composite end point, but was more effective in reducing proven emergent fungal infections, infusion-related toxicities, and nephrotoxicity. The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional therapy. Patients and Methods: Itemized hospital billing data were collected on 414 patients from 19 of the 32 centers that participated in the trial. Hospital length of stay and costs from the first dose of study medication to the time of hospital discharge were assessed. Results: Hospital costs from the time of first dose to discharge were significantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P = .022). However, hospital costs were highly sensitive to the cost of study medication ($39,648 v $43,048 when drug costs were not included; P = .416). Using decision analysis models and sensitivity analyses to vary the cost of study medications and the risk of nephrotoxicity, the break-even points for the cost of liposomal therapy were calculated to range from $72 to $87 per 50 mg for all patients and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients. Conclusion: The cost of liposomal amphotericin B and patient risk for developing nephrotoxicity play large roles in determining whether liposomal amphotericin B is cost-effective as first-line empirical therapy in persistently febrile neutropenic patients. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: In a randomized, double-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients, using a composite end point, but was more effective in reducing proven emergent fungal infections, infusion-related toxicities, and nephrotoxicity. The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional therapy. Patients and Methods: Itemized hospital billing data were collected on 414 patients from 19 of the 32 centers that participated in the trial. Hospital length of stay and costs from the first dose of study medication to the time of hospital discharge were assessed. Results: Hospital costs from the time of first dose to discharge were significantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P = .022). However, hospital costs were highly sensitive to the cost of study medication ($39,648 v $43,048 when drug costs were not included; P = .416). Using decision analysis models and sensitivity analyses to vary the cost of study medications and the risk of nephrotoxicity, the break-even points for the cost of liposomal therapy were calculated to range from $72 to $87 per 50 mg for all patients and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients. Conclusion: The cost of liposomal amphotericin B and patient risk for developing nephrotoxicity play large roles in determining whether liposomal amphotericin B is cost-effective as first-line empirical therapy in persistently febrile neutropenic patients. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034045794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034045794&partnerID=8YFLogxK

M3 - Article

C2 - 10856108

AN - SCOPUS:0034045794

VL - 18

SP - 2476

EP - 2483

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -